Quince Therapeutics (QNCX) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

QNCX · Stock Price

USD 1.30+0.28 (+27.45%)

Market Cap: $20.5M

Historical price data

Market Cap: $20.5MPipeline: 8 drugs (4 Phase 3)Founded: 2018HQ: South San Francisco, United States

Sector Ranking#327 in Small Molecule Drugs #82 in Neuroscience & CNS

Overview

Quince Therapeutics is a clinical-stage biotech focused on transforming proven therapeutics through its innovative Autologous Intracellular Drug Encapsulation (AIDE) platform, which leverages a patient's own red blood cells for targeted, safer drug delivery. The company's most advanced candidate, eDSP, recently reported topline results from a pivotal Phase 3 trial in Ataxia-Telangiectasia (A-T), which did not meet its primary or key secondary endpoints, prompting a strategic review. Quince's strategy hinges on leveraging the AIDE platform's potential to improve the therapeutic index of corticosteroids and other drugs across multiple chronic inflammatory and rare diseases, though its near-term future is contingent on the outcome of its exploration of strategic alternatives.

Rare DiseasesNeurodegenerativeInflammatory

Technology Platform

Proprietary Autologous Intracellular Drug Encapsulation (AIDE) platform, an automated drug/device combination that encapsulates therapeutics into a patient's own red blood cells to improve safety, biodistribution, and pharmacokinetics.

Pipeline

8

8 drugs in pipeline4 in Phase 3

Drug	Indication	Stage
Dexamethasone	Crohn's Disease	Phase 3
EryDex Low dose DSP + EryDex High dose DSP + Pooled Placebo	Nervous System Disease	Phase 3
Dexamethasone sodium phosphate	Ataxia Telangiectasia	Phase 3
Dexamethasone sodium phosphate	Ataxia Telangiectasia	Phase 3
Dex 21-P + Placebo	Ulcerative Colitis	Phase 2

Funding History

2

Total raised:$131M

IPO$86MUndisclosedJul 15, 2020

Series A$45MMorningside VenturesJun 15, 2019

Opportunities

The AIDE platform holds theoretical potential to revolutionize the chronic use of corticosteroids and other toxic drugs across a wide range of inflammatory and autoimmune diseases, representing a multi-billion dollar market.

In the near term, the strategic review process could deliver value to shareholders through a merger or acquisition that recognizes the platform's IP value.

Risk Factors

The company faces existential risk following the failure of its lead Phase 3 program, with its future entirely dependent on an uncertain strategic review process.

The core AIDE technology platform remains unproven at a pivotal clinical level, and the company has limited financial resources and a depleted market capitalization.

Competitive Landscape

In Ataxia-Telangiectasia, Quince faced little direct competition due to the absence of approved therapies, though its trial failure leaves the field open. For its platform, it competes conceptually with a broad array of novel drug delivery technologies, and must demonstrate clear clinical superiority to gain traction.